United Arab Emirates (UAE) Orphan Drugs Market (2024-2030) Outlook | Share, Value, Companies, Industry, Analysis, Revenue, Forecast, Trends, Growth & Size

Market Forecast By Drugs (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris, Other Orphan Drugs), By Drug Type (Biologics, Non-Biologics), By Therapy Class (Oncology, Blood, Endocrine, Central Nervous Systems, Cardiovascular, Respiratory) And Competitive Landscape
Product Code: ETC070139 Publication Date: Aug 2023 Updated Date: Jan 2024 Product Type: Report
Publisher: 6Wresearch No. of Pages: 70 No. of Figures: 35 No. of Tables: 5

United Arab Emirates (UAE) Orphan Drugs Market Synopsis

The United Arab Emirates (UAE) orphan drugs market has been experiencing significant growth, driven by the increasing focus on rare diseases and personalized medicine. Orphan drugs are medications developed to treat rare medical conditions that affect a small number of patients. In the UAE, as the awareness of rare diseases grows and the government supports initiatives for rare disease management, the demand for orphan drugs has seen a surge. The market`s growth is influenced by the UAE healthcare investments, regulatory incentives for orphan drug development, and the need for improved patient outcomes in rare disease populations.

Drivers of the Market

The growth of the UAE orphan drugs market is propelled by several key drivers. Firstly, the rising prevalence of rare diseases and genetic disorders has led to an increased focus on developing targeted therapies. Orphan drugs provide treatment options for conditions that were previously underserved, offering hope to patients and their families. Secondly, the UAE regulatory framework provides incentives for pharmaceutical companies to invest in orphan drug development, including extended market exclusivity and faster approval pathways. These incentives have attracted global biopharmaceutical companies to introduce their orphan drug portfolios in the UAE.

Challenges of the Market

Despite the positive market outlook, the UAE orphan drugs market faces certain challenges. One significant challenge is the high cost of orphan drugs due to their limited patient populations, leading to potential affordability issues for patients and healthcare systems. Ensuring equitable access to orphan drugs for all eligible patients remains a priority for healthcare policymakers. Additionally, the limited awareness and knowledge about rare diseases among healthcare professionals and the general public may delay accurate diagnosis and treatment initiation.

Covid-19 Impact on the Market

The Covid-19 pandemic, which emerged in 2020, had an impact on the UAE orphan drugs market. While the pandemic initially diverted healthcare resources and attention to Covid-19 management, it also highlighted the vulnerability of patients with rare diseases. The need for continued access to orphan drugs and rare disease management remained a key focus during the pandemic, leading to increased advocacy for rare disease patients and their specific healthcare needs.

Key Players of the Market

The UAE orphan drugs market is experiencing substantial growth, driven by increasing awareness of rare diseases and the need for specialized treatments. Orphan drugs, designed to treat rare medical conditions, have gained significant attention in the region, providing hope to patients and families facing these challenging health conditions. Key players at the forefront of advancing rare disease treatments in the UAE include pharmaceutical companies such as Novartis AG, Roche Holdings AG (part of Roche Group), and Sanofi S.A. These industry leaders are actively investing in research and development to develop and commercialize orphan drugs, working closely with healthcare stakeholders to improve access and affordability for patients. Additionally, local companies like Gulf Pharmaceutical Industries (Julphar) are contributing to the market`s expansion and supporting domestic research and manufacturing capabilities. As the UAE continues to prioritize rare disease management and access to orphan drugs, the orphan drugs market is set to witness further growth, fostering better outcomes for patients affected by rare medical conditions.

Key Highlights of the Report:

  • United Arab Emirates (UAE) Orphan Drugs Market Outlook
  • Market Size of United Arab Emirates (UAE) Orphan Drugs Market, 2020
  • Forecast of United Arab Emirates (UAE) Orphan Drugs Market, 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Revenues & Volume for the Period 2023 - 2027
  • United Arab Emirates (UAE) Orphan Drugs Market Trend Evolution
  • United Arab Emirates (UAE) Orphan Drugs Market Drivers and Challenges
  • United Arab Emirates (UAE) Orphan Drugs Price Trends
  • United Arab Emirates (UAE) Orphan Drugs Porter's Five Forces
  • United Arab Emirates (UAE) Orphan Drugs Industry Life Cycle
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Drugs for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Revlimid for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Rituxan for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Opdivo for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Keytruda for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Imbruvica for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Soliris for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Other Orphan Drugs for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Drug Type for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Biologics for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Non-Biologics for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Therapy Class for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Oncology for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Blood for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Endocrine for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Central Nervous Systems for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Cardiovascular for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume By Respiratory for the Period 2023 - 2027
  • United Arab Emirates (UAE) Orphan Drugs Import Export Trade Statistics
  • Market Opportunity Assessment By Drugs
  • Market Opportunity Assessment By Drug Type
  • Market Opportunity Assessment By Therapy Class
  • United Arab Emirates (UAE) Orphan Drugs Top Companies Market Share
  • United Arab Emirates (UAE) Orphan Drugs Competitive Benchmarking By Technical and Operational Parameters
  • United Arab Emirates (UAE) Orphan Drugs Company Profiles
  • United Arab Emirates (UAE) Orphan Drugs Key Strategic Recommendations
Frequently Asked Questions About the Market Study (FAQs):
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 United Arab Emirates (UAE) Orphan Drugs Market Overview

3.1 United Arab Emirates (UAE) Country Macro Economic Indicators

3.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, 2020 & 2027F

3.3 United Arab Emirates (UAE) Orphan Drugs Market - Industry Life Cycle

3.4 United Arab Emirates (UAE) Orphan Drugs Market - Porter's Five Forces

3.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Drugs, 2020 & 2027F

3.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2020 & 2027F

3.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2020 & 2027F

4 United Arab Emirates (UAE) Orphan Drugs Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.3 Market Restraints

5 United Arab Emirates (UAE) Orphan Drugs Market Trends

6 United Arab Emirates (UAE) Orphan Drugs Market, By Types

6.1 United Arab Emirates (UAE) Orphan Drugs Market, By Drugs

6.1.1 Overview and Analysis

6.1.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Drugs, 2018 - 2027F

6.1.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Revlimid, 2018 - 2027F

6.1.4 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Rituxan, 2018 - 2027F

6.1.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Opdivo, 2018 - 2027F

6.1.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Keytruda, 2018 - 2027F

6.1.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Imbruvica, 2018 - 2027F

6.1.8 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Soliris, 2018 - 2027F

6.2 United Arab Emirates (UAE) Orphan Drugs Market, By Drug Type

6.2.1 Overview and Analysis

6.2.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Biologics, 2018 - 2027F

6.2.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2018 - 2027F

6.3 United Arab Emirates (UAE) Orphan Drugs Market, By Therapy Class

6.3.1 Overview and Analysis

6.3.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Oncology, 2018 - 2027F

6.3.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Blood, 2018 - 2027F

6.3.4 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Endocrine, 2018 - 2027F

6.3.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2018 - 2027F

6.3.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2018 - 2027F

6.3.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Respiratory, 2018 - 2027F

7 United Arab Emirates (UAE) Orphan Drugs Market Import-Export Trade Statistics

7.1 United Arab Emirates (UAE) Orphan Drugs Market Export to Major Countries

7.2 United Arab Emirates (UAE) Orphan Drugs Market Imports from Major Countries

8 United Arab Emirates (UAE) Orphan Drugs Market Key Performance Indicators

9 United Arab Emirates (UAE) Orphan Drugs Market - Opportunity Assessment

9.1 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Drugs, 2020 & 2027F

9.2 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Drug Type, 2020 & 2027F

9.3 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2020 & 2027F

10 United Arab Emirates (UAE) Orphan Drugs Market - Competitive Landscape

10.1 United Arab Emirates (UAE) Orphan Drugs Market Revenue Share, By Companies, 2020

10.2 United Arab Emirates (UAE) Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Pricing
  • Single User License
    $ 1,995
  • Department License
    $ 2,400
  • Site License
    $ 3,120
  • Global License
    $ 3,795
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Industry Events and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All